Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Teva Pharmaceutical Industries Ltd. Director's Dealing 2025

Nov 18, 2025

7082_dirs_2025-11-18_77419a78-a4bb-4bc4-9aa4-325a5ccb964b.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
CIK: 0000818686
Period of Report: 2025-11-14

Reporting Person: Fox Christine (N/A)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-11-14 Ordinary Shares S 30000 $25.1107 Disposed 28384 Direct

Footnotes

F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.